[
  {
    "id": "alert-high-1757331001644-c6rholcoj",
    "company": "Replimune",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-1odifdwwg",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNT0w3NDFEdGlZTG51M1VtMnZhS21xSGlCNjA5U0dTeTZmS01iUDFHbGNvR3R4Szl2LThwcE1ETjVtTmFOUFQ5ZzFZQUdwa3ZSWEZGR2s5YnBOZzVkZHpaNVQ5MHlVRndUaHlCZXRjVXd4cnY0UmhxbVBycjVSX19oaVNKdnI5UmlLQWZwSUllLVBqQ3RvQTNHN3JCUzdxT3M5S0E0X2ZWVEJWelBZR3Fyek9XNUZhcGc?oc=5",
    "summary": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application  geneonline.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-zd7r4zeik",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-2bm28am76",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-11-19T08:00:00.000Z",
    "title": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY) - Modern Retina",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZUhiM1ZrQ20xX0NZb3hEQlZzczhsV04yQlZkdldQMjBzTm94UjBfd3A3TlhjX0xVMGtHWWZzak9ONnBjR1JMTUFqYlpIMW9zNHFLTzRoc3dtV1Fqa05KVlVxckVWUXRSakJTNV9sb2RoWGpEUFpvZjY2TDhMT2tiTjV4TUhJcGNyR2NuSXBDam9mU0VUazVWWlAtRjJMU3A1Ymw1TXZRb21rZXh4Tjc5N2xfUnZpX2hyMXo2WjVEUGMxRjky?oc=5",
    "summary": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)  Modern Retina",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-v0fmr2f69",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-rblgwt7n0",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-8a29thpe5",
    "company": "Astellas",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:33.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-7gkyn1ltx",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-ni3sg2cj8",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-nq2a20pw3",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-c50hkeqlz",
    "company": "Ultragenyx Pharmaceutical Inc",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-rb6zzl7cf",
    "company": "Treat",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-b6q67phxa",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-ofwl8jx6g",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-arsxrzin5",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-ni8miw3bw",
    "company": "Reproxalap",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-hamilwzlp",
    "company": "Subcutaneo",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-4dpvy6sep",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-3qkz7pw5w",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-1rdzqnjri",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-dv1w7wvdd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-0o0ig2go6",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-u1gev1e9x",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-esy1z0icx",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-x16gptby9",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-9jeb6gvwm",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-w7gcfyegn",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-j3oliwmfj",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001644-as5fkpdq0",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-08T11:30:01.644Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-bp4bde7si",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-3qg1pc0un",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-9c13t2hjt",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-qzuiktqco",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-wehzigqdu",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-ci7hli1lf",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-pukmgt7xl",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-hif8p3dlt",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-u9ixzuwrj",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T17:28:42.000Z",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-cnl2m1qso",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-jkvaqybyh",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-j93369kkw",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-3j93oc7s1",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-sm6of7vyy",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-j2h49gpxj",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-lc2hb9bip",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-1r2cgyd1p",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-m8ntr337c",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T16:10:06.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757331001643-zmaz4rmrg",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-08T11:30:01.643Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-odhz2ne3f",
    "company": "Replimune",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-g5cb331ao",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNT0w3NDFEdGlZTG51M1VtMnZhS21xSGlCNjA5U0dTeTZmS01iUDFHbGNvR3R4Szl2LThwcE1ETjVtTmFOUFQ5ZzFZQUdwa3ZSWEZGR2s5YnBOZzVkZHpaNVQ5MHlVRndUaHlCZXRjVXd4cnY0UmhxbVBycjVSX19oaVNKdnI5UmlLQWZwSUllLVBqQ3RvQTNHN3JCUzdxT3M5S0E0X2ZWVEJWelBZR3Fyek9XNUZhcGc?oc=5",
    "summary": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application  geneonline.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-u1y6h73cj",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-8jb216hf4",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-11-19T08:00:00.000Z",
    "title": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY) - Modern Retina",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZUhiM1ZrQ20xX0NZb3hEQlZzczhsV04yQlZkdldQMjBzTm94UjBfd3A3TlhjX0xVMGtHWWZzak9ONnBjR1JMTUFqYlpIMW9zNHFLTzRoc3dtV1Fqa05KVlVxckVWUXRSakJTNV9sb2RoWGpEUFpvZjY2TDhMT2tiTjV4TUhJcGNyR2NuSXBDam9mU0VUazVWWlAtRjJMU3A1Ymw1TXZRb21rZXh4Tjc5N2xfUnZpX2hyMXo2WjVEUGMxRjky?oc=5",
    "summary": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)  Modern Retina",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-5kts3m6nb",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-6yy1sahf8",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-o8y3mqcqt",
    "company": "Astellas",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:33.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-9yjqa2b76",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-y91r6qijf",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-bpj4u0hvk",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-ng6mu3vr0",
    "company": "Ultragenyx Pharmaceutical Inc",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-obw1xg2mk",
    "company": "Treat",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-d0eal7pg9",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-vx2e2vf34",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-5lylkclpf",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-jxc8q5dff",
    "company": "Reproxalap",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-ev6i0g3mn",
    "company": "Subcutaneo",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-8o3c0w362",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-sgnc20r2n",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-tfkmykk4x",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-e93nzb2er",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-goal23t4o",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-r1gaq5g7j",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-9hygh5a8h",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-i015xn5bi",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-viea5rwkz",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-27gqm6mse",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-17w9pncm7",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-anx9bhr3e",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-zr1l95qg1",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-3bzd3foe9",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-br5sr9x8z",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-303w1spil",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-nvxc06pmb",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-m2anxtua7",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-3bn2rzmgv",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791572-yazslqy9r",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-08T11:26:31.572Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-m2wna63ae",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T17:28:42.000Z",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-jv3692kas",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-nt2qfso51",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-snryr3t93",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-9hj62ft7y",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-en73sns3b",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-3dv975drp",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-kjf5fpqyw",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-s13tn1ps5",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791571-bb6y0cgd8",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T16:10:06.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-08T11:26:31.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330791569-l5o9dmww3",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-08T11:26:31.569Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-uxrp7kxjg",
    "company": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTHUxdXliYVhkdDUzQTJtZFBuN3oxQzlub3FHaVVtclNlOHQtTHNSdWNPYzhiWXdST2V1VnlMSlBmLVdvSFEwLUsxMXk4WTgzUkE3N1ZSOUp6Mk1tTnZCb0tLY1RITmRoY3YzdS1PVkdBVW5nYkJFV1dDdVdFNzFhWFhSX2QzQ3gxa21vMEhSYWJfZWREMFZRckN2ZFJaTmNGZ01jNHhXc0NIaEZuM0RieV80dnFpZmFNM2J5MHRLODdJYnBJMi1EeDQ5aWs2ZUJ4WW80bkxUaw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Replimune Over Insufficient Efficacy Data for Advanced Melanoma Treatment  geneonline.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-ijkcrbpy8",
    "company": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNT0w3NDFEdGlZTG51M1VtMnZhS21xSGlCNjA5U0dTeTZmS01iUDFHbGNvR3R4Szl2LThwcE1ETjVtTmFOUFQ5ZzFZQUdwa3ZSWEZGR2s5YnBOZzVkZHpaNVQ5MHlVRndUaHlCZXRjVXd4cnY0UmhxbVBycjVSX19oaVNKdnI5UmlLQWZwSUllLVBqQ3RvQTNHN3JCUzdxT3M5S0E0X2ZWVEJWelBZR3Fyek9XNUZhcGc?oc=5",
    "summary": "Ultragenyx Receives FDA Complete Response Letter for UX111 Biologics License Application  geneonline.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-pq9cp1tc8",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-z26pvkd59",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2024-11-19T08:00:00.000Z",
    "title": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY) - Modern Retina",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZUhiM1ZrQ20xX0NZb3hEQlZzczhsV04yQlZkdldQMjBzTm94UjBfd3A3TlhjX0xVMGtHWWZzak9ONnBjR1JMTUFqYlpIMW9zNHFLTzRoc3dtV1Fqa05KVlVxckVWUXRSakJTNV9sb2RoWGpEUFpvZjY2TDhMT2tiTjV4TUhJcGNyR2NuSXBDam9mU0VUazVWWlAtRjJMU3A1Ymw1TXZRb21rZXh4Tjc5N2xfUnZpX2hyMXo2WjVEUGMxRjky?oc=5",
    "summary": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)  Modern Retina",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-j7chvoi10",
    "company": "Unicycive stock falls as FDA plans complete response letter for OLC",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-y2qyohfsq",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-xfhp14w5t",
    "company": "Astellas receives Complete Response Letter from FDA for Izervay sNDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:33.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-ldd2ewlgb",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-8t0itbnmy",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-qbxgaltkk",
    "company": "Capricor",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-n86sl0ix5",
    "company": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-hf3hdjlor",
    "company": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-d3sr13mzn",
    "company": "FDA Issues Complete Response Letter for Much",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-i67gawc0z",
    "company": "FDA Issues Complete Response Letter for Etripamil for PSVT",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-6hfo9lhdu",
    "company": "Milestone submits response to FDA Complete Response Letter over Cardamyst",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-janp1c3cy",
    "company": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-lvlh67480",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-8z11ikqo1",
    "company": "PTC Therapeutics Receives FDA Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - MSN",
    "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZmI0WlRSMDNhNURtOWxSbkJrLVY3UFFNODhiTmxEc3NxeTB6VEhVSURFWEh5VUxCTFZKLUJsT2lEZjVlcEhlM3Rpb2htdjdLcnVoLURIcHhxaDcxVFI2YVRtOWNET0Q0OVVEU3ZtQkZVaGpTQWNuUXR2anotbHdpY3ZGTkZzU2V3OGQ2bFoxVDdtaG5CWDgyRnhHRXNkWXJqY2lpVzlKeEc?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  MSN",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-8ltwit4x4",
    "company": "Ultragenyx Receives Complete Response Letter from FDA for",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-op9h3ablw",
    "company": "FDA issues complete response letter for Ultragenyx gene therapy application",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-q291u2nui",
    "company": "Telix stock plunges after FDA issues Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-6tp5cy2f7",
    "company": "FDA Issues Complete Response Letter for Tab",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-d0jesn6oe",
    "company": "Unapproved Drugs",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-hw2vq80bb",
    "company": "FDA Issues Complete Response Letter for Glofit",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720496-pd6v0xsdc",
    "company": "FDA hits Unicycive with manufacturing",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-08T11:25:20.496Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-ia2a67pgy",
    "company": "TLX101",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-s3znwpwv8",
    "company": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-347nafjw6",
    "company": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-l1c72dgw9",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-ubs9ijlzt",
    "company": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-gbamr747c",
    "company": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-pwvaoi3k3",
    "company": "Ultragenyx receives complete response letter for UX111 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-7mwfxt0xf",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-9r29ij7x1",
    "company": "FDA received complete response letter from FDA for Columvi in DLBCL",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-z2nlytzn2",
    "company": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-hemb894j4",
    "company": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-1m1qvcj7n",
    "company": "FDA Issues Complete Response Letter to Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-3gye36yx9",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T17:28:42.000Z",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-1ikhxlna0",
    "company": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-4wz2gmer4",
    "company": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-zsj3q31q5",
    "company": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-0b4dtvwx6",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-serd3p3q4",
    "company": "MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-31axl4woj",
    "company": "FDA issues complete response letter for 89Zr",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-cjqhmi9v0",
    "company": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-d9m5ht3n8",
    "company": "FDA Releases Complete Response Letter on Declining MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-jmrmctx2k",
    "company": "BREAKING",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T16:10:06.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757330720495-2zc9sffao",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-08T11:25:20.495Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201699-02u5iv82s",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T20:00:01.699Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201699-z9bffgvrl",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T20:00:01.699Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201699-3vry990pp",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T20:00:01.699Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201699-s6xlhtizf",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T20:00:01.699Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-efhl8k1hn",
    "company": "Replimune",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-486wvji50",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-34ak7oorx",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-3fr5646ci",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-bwiaw1trh",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-6b87zoush",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-uueqh53wh",
    "company": "Ultragenyx Pharmaceutical Inc",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-t0z18dmgm",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-vbz68t279",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-rn6ngy0ty",
    "company": "Reproxalap",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-54ln3m43h",
    "company": "Subcutaneo",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-12lcxgxgu",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-g49r7a9c1",
    "company": "Treat",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-vkhxcv5g9",
    "company": "Astellas",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:34.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-l4gx87cdd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-y13lr8bop",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-9pcnsredf",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-9b9xcsvfh",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-p3le1i4yr",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-oivmnfkrm",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-7jzm5i7j8",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-12xpx7d1f",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-u5iomfco3",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-uetf7gbbd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-hyr8u6hwt",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-t85v3l2qn",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-yqhgh6j30",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-n9g77dhcw",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-cf1gmz987",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-lwnzkkfkj",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-6c29wqstq",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-frdalhk1v",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-wxkue2unk",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-tp6gsyj8c",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-rdbbadkja",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-txbfe5wnv",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-7tmdf5ns8",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-v81bhl99p",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-8fwe4a45n",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-mnct3h7y1",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-vx5efbme6",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201698-2yxfjz182",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T13:49:44.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-07T20:00:01.698Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757275201697-keemz702r",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-07T20:00:01.697Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-ulgsygfum",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-nyw6mrut8",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-zjr9nv2pa",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-rehw2kved",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-7xpoyexwn",
    "company": "Replimune",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-m2x4dahg5",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-8iygnwbvv",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-olsdl4wal",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-g422v2uiq",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-urv8c513q",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-ac9wjzuzr",
    "company": "Ultragenyx Pharmaceutical Inc",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-8svp5sri2",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-io0hnamg1",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-fbb1yfm9e",
    "company": "Reproxalap",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-bjw9tuqyq",
    "company": "Subcutaneo",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-a0mncqqpd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-l8rbq6snl",
    "company": "Treat",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-vgake9gn6",
    "company": "Astellas",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:34.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-061c1h17w",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-odrgqv13w",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-pyojbz71o",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-f76zskbsh",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-qnz6v64rk",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-ew5tzcw78",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-wdekcmzpt",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-rnv0qqirk",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-3fyf6a21y",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-jygnsregq",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-hrhfuka1k",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-y3c8e4aqc",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-ys8dzw8en",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-l9i8ozn7o",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-q2d01pzs7",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775839-iwe03y0s6",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-07T19:52:55.839Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-5qmqr2h8w",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-h919seemo",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-v5z5jqgbl",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-mt3ck8w8h",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-vu3v8rweo",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-zk7ps3t1w",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-n3va8h9nd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-4bwuki63k",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-vw6z5hudw",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-o13rr6b6f",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-b1n298dr0",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775838-xbnlpwvrl",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T13:49:44.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-07T19:52:55.838Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757274775837-p9qr27zxt",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-07T19:52:55.837Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-nk5n994lw",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-od572u5pv",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-e1boxsj45",
    "company": "Unicycive stock falls as FDA plans complete response letter for OLC",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-eek96ol0b",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-fwy4nuhe3",
    "company": "Replimune receives complete response letter from FDA for RP1 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-wlaz83y5t",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-99oc7lbel",
    "company": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-h7kha5z56",
    "company": "PTC Therapeutics Receives FDA Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-filr55zmp",
    "company": "FDA Issues Complete Response Letter for Much",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401321-4jvmv3qm9",
    "company": "Capricor",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T19:30:01.321Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-corrh5wq7",
    "company": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-xb11y2vua",
    "company": "FDA Issues Complete Response Letter for Etripamil for PSVT",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-ps71v7pby",
    "company": "Milestone submits response to FDA Complete Response Letter over Cardamyst",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-6k6xie5bi",
    "company": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-vssh8ooav",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-ibzgoqn1b",
    "company": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-7q38pm4cf",
    "company": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-e1bir5qpw",
    "company": "Astellas receives Complete Response Letter from FDA for Izervay sNDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:34.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-aylfxvdp2",
    "company": "FDA Issues Complete Response Letter for Tab",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-qxn0jm8ux",
    "company": "Ultragenyx Receives Complete Response Letter from FDA for",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-awbypshlx",
    "company": "FDA issues complete response letter for Ultragenyx gene therapy application",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-17nfp6jv8",
    "company": "Telix stock plunges after FDA issues Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-fppcalfdc",
    "company": "FDA Issues Complete Response Letter for Glofit",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-2dn0t9fim",
    "company": "TLX101",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-k3t0e61jv",
    "company": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-q4hod8pss",
    "company": "FDA hits Unicycive with manufacturing",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-ujl8dksz3",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-92cblz2ge",
    "company": "Unapproved Drugs",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401320-z57h3v1zm",
    "company": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-c9sivk4zc",
    "company": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-07T19:30:01.320Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-7yj8a36wb",
    "company": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-2y1ytgdt9",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-32jiypqhm",
    "company": "Ultragenyx receives complete response letter for UX111 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-yyjigxpz6",
    "company": "FDA received complete response letter from FDA for Columvi in DLBCL",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-0r463aozm",
    "company": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-vykwspqul",
    "company": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-mnv5dib48",
    "company": "FDA Issues Complete Response Letter to Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-k6u8h4unl",
    "company": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-6bhfidgsn",
    "company": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-jcrkua83v",
    "company": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-c7qhdzawv",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-31ragy6ig",
    "company": "FDA issues complete response letter for 89Zr",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-bf45numjt",
    "company": "MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-fo9ww2n43",
    "company": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-n0cy3lj6s",
    "company": "FDA Releases Complete Response Letter on Declining MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401319-ko291wyg8",
    "company": "BREAKING",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T13:49:44.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-07T19:30:01.319Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757273401318-dq12lrdw8",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-07T19:30:01.318Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-pq1dea3rb",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-f4qp00qva",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-87w4uv4zc",
    "company": "Replimune receives complete response letter from FDA for RP1 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-zwgaqy0fe",
    "company": "Unicycive stock falls as FDA plans complete response letter for OLC",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-g98scg5pm",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-5lpcjv04x",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-7vgqvszvh",
    "company": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-ihaxkzvo6",
    "company": "Astellas receives Complete Response Letter from FDA for Izervay sNDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:33.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-4f2iedkr6",
    "company": "PTC Therapeutics Receives FDA Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-xmkroxas1",
    "company": "Capricor",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-lnk135xmc",
    "company": "FDA Issues Complete Response Letter for Much",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-qv2hd63rt",
    "company": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650986-u3vi7u3cz",
    "company": "FDA Issues Complete Response Letter for Etripamil for PSVT",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T18:10:50.986Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-ps3iujk8f",
    "company": "Milestone submits response to FDA Complete Response Letter over Cardamyst",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-26hdai113",
    "company": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-n0s85kvit",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-gtg0o41gh",
    "company": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-nrp192hp7",
    "company": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-i41znk9q9",
    "company": "FDA Issues Complete Response Letter for Tab",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-di2g4lbt4",
    "company": "Ultragenyx Receives Complete Response Letter from FDA for",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-9cpupb17s",
    "company": "FDA issues complete response letter for Ultragenyx gene therapy application",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-0x7n97jc7",
    "company": "Telix stock plunges after FDA issues Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-soi4gzxr9",
    "company": "FDA Issues Complete Response Letter for Glofit",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-a3rs16yq6",
    "company": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-n9y1ug165",
    "company": "TLX101",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-mez0i65bg",
    "company": "FDA hits Unicycive with manufacturing",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-r7u4l7gf4",
    "company": "Unapproved Drugs",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-yyzyrtpmb",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-kjm8mfkv7",
    "company": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-4j5zm2ykz",
    "company": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-6ymq1in27",
    "company": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-lul656c7j",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-qrxb4657e",
    "company": "Ultragenyx receives complete response letter for UX111 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-4tof5a32n",
    "company": "FDA received complete response letter from FDA for Columvi in DLBCL",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650985-0mddty5mj",
    "company": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-07T18:10:50.985Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650984-a0q34mirt",
    "company": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650984-wbo0axjs0",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T17:28:42.000Z",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650984-mb94flsnr",
    "company": "FDA Issues Complete Response Letter to Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650984-sjles90jx",
    "company": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650984-6evivs2ny",
    "company": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650984-hmrhdq7lh",
    "company": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650984-c4v8cj8kk",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650983-k2tn42xra",
    "company": "FDA issues complete response letter for 89Zr",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-07T18:10:50.984Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650983-1wun70mid",
    "company": "MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-07T18:10:50.983Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650983-7qdri2kw6",
    "company": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-07T18:10:50.983Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650983-zwwyhry8p",
    "company": "FDA Releases Complete Response Letter on Declining MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-07T18:10:50.983Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650983-4jukwbf7k",
    "company": "BREAKING",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T13:49:44.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-07T18:10:50.983Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268650983-uy82f7h1z",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-07T18:10:50.983Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-mewskjbit",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-getg5rn9m",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-iujf6wstj",
    "company": "Replimune",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-aoqzbvrdr",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-1oukr7rtb",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-vkpgtlbkp",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-vogo71pv7",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-bpkhurd0q",
    "company": "Astellas",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:33.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-1ovg59rlr",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-g66tvoiwt",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-o2xy73f59",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-q7yky95pm",
    "company": "Ultragenyx Pharmaceutical Inc",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-v9kjthzgs",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-snzmfuw61",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-nefbfp9lh",
    "company": "Reproxalap",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-om974x5o7",
    "company": "Subcutaneo",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-7z8cz6w78",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-sqfjtkjo7",
    "company": "Treat",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-eqrxbk8e2",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-gfpxto9px",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-9zvddh32j",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-96qav9hqs",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-pimpmkast",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-tmi1fdl50",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-ca3qvp0wq",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-yb3gbpanj",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-lzx1k7w39",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-opwwjrud9",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-rri6v0ndx",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589687-rlu9cqk7x",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-07T18:09:49.687Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-aa7e4xphv",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-nu75c366c",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-mm5vie464",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-xzj8nxljs",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-g0wmygp9t",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-g3qvl2nm5",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-dpbllnalx",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T17:28:42.000Z",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-uc2px0zmy",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-slxmnwhoc",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-w0p8z099m",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-t1wx9ntbd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-0fs0p1rs7",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-xgmx4el71",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-s3qnz80bw",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-fub6cboqa",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-s23jmmadj",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589686-78f16xzek",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T13:49:44.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-07T18:09:49.686Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268589656-9rm9f4gnb",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-07T18:09:49.656Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-sz2vskdrb",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-8369znsx9",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-11-19T08:00:00.000Z",
    "title": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY) - Modern Retina",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNZUhiM1ZrQ20xX0NZb3hEQlZzczhsV04yQlZkdldQMjBzTm94UjBfd3A3TlhjX0xVMGtHWWZzak9ONnBjR1JMTUFqYlpIMW9zNHFLTzRoc3dtV1Fqa05KVlVxckVWUXRSakJTNV9sb2RoWGpEUFpvZjY2TDhMT2tiTjV4TUhJcGNyR2NuSXBDam9mU0VUazVWWlAtRjJMU3A1Ymw1TXZRb21rZXh4Tjc5N2xfUnZpX2hyMXo2WjVEUGMxRjky?oc=5",
    "summary": "US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)  Modern Retina",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-i2e2iindc",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-e6tc7mdnc",
    "company": "Replimune",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-zoir2s4ue",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-5p20x4plf",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-m49n2zw1r",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-dcft644x1",
    "company": "Astellas",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:33.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-0kevps91f",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-5i5k8gddo",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-90b9r3d72",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-j5ixkc8uc",
    "company": "Ultragenyx Pharmaceutical Inc",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-ozjpewt4v",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-exvyagpjm",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-9c51va9x6",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-2h5i1hu5g",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-t0gx0wgol",
    "company": "Treat",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-94k6799ss",
    "company": "Reproxalap",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-z2bsd6krq",
    "company": "Subcutaneo",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-2u1itaxoy",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-0fgp5kqw9",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-bc6nmea58",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-km4zd84mi",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-3aeambpxo",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-c2ljm9ufc",
    "company": "PTC",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365571-itq9wcya4",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-07T18:06:05.571Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-2xdkbpomg",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-n5osqcyzd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-s0y9aj1ag",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-w66r6ni2t",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-9yxdxk1c3",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-iznzre7kq",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-mv16thlto",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-ky6f5dlzo",
    "company": "Ultragenyx",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-7aehjpe84",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-43aslp6r6",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-r3ob03zyl",
    "company": "Manufacturer",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-ohaec9x67",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T17:28:42.000Z",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-a9ma64hqj",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-aat1iwupq",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-frm1liqdf",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-oxtve68wk",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-9b39159zd",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-zque8iq0w",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-nfss393at",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365570-990n7d4eh",
    "company": "Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-07T18:06:05.570Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365569-jk11pdurt",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-07T18:06:05.569Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365569-ucz56rt8r",
    "company": "re",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T13:49:44.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-07T18:06:05.569Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268365541-cvctn6npj",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-07T18:06:05.541Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001628-cb138af7o",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T18:00:01.628Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001628-idt55sdu4",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T18:00:01.628Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001628-wfg4ss7z1",
    "company": "Unicycive stock falls as FDA plans complete response letter for OLC",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T18:00:01.628Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-qf2uorg4z",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-tx3mz8qxg",
    "company": "Replimune receives complete response letter from FDA for RP1 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-7xkm4xnsl",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-boo5drlne",
    "company": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-vx1tmaj9r",
    "company": "PTC Therapeutics Receives FDA Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-td3ckor8a",
    "company": "FDA Issues Complete Response Letter for Much",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-5z7pekrx8",
    "company": "Capricor",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-2553i9v7m",
    "company": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-8xwtarn65",
    "company": "FDA Issues Complete Response Letter for Etripamil for PSVT",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-jr29872wd",
    "company": "Milestone submits response to FDA Complete Response Letter over Cardamyst",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-fz4yxdh2m",
    "company": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-r7tnq2r6l",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-lecap75h3",
    "company": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-5ssujijp2",
    "company": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-wnrr4907i",
    "company": "Astellas receives Complete Response Letter from FDA for Izervay sNDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:34.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-ef0plr476",
    "company": "FDA Issues Complete Response Letter for Tab",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-rk20wpnjx",
    "company": "Ultragenyx Receives Complete Response Letter from FDA for",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-2v5jg0e15",
    "company": "FDA issues complete response letter for Ultragenyx gene therapy application",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001627-4sc9lqnif",
    "company": "Telix stock plunges after FDA issues Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-h30cwhx29",
    "company": "FDA Issues Complete Response Letter for Glofit",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-18T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPOEp5QUp6MFBYajNKQlptc0lpeWc2MGZYb3E1ckR5MW1GUUhDS2w0TWhWdjFpeVpUbWh3THZPRWJaeDZQWFloem5sZnJUaHh1cTFtWDd4dnJBb2h3MTdWTDBHVnd6cjdtREt0MGFiWjJWcEF5dldvajV5ZlFyQjRKRDBxYTNtUGg3ZHljdnBhdEo5UmFibE1CcVFnNFVBaWhnaHc?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofit-GemOx in R/R DLBCL  Pharmacy Times",
    "created": "2025-09-07T18:00:01.627Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-5xdgogtme",
    "company": "TLX101",
    "type": "crl",
    "severity": 9,
    "date": "2025-05-06T07:00:00.000Z",
    "title": "TLX101-CDx Given Complete Response Letter for Glioma Imaging - Oncology Nursing News",
    "link": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZjdnbUFDSFlpQkV5UkFOcTVxYThqYWJhNm9OMEEwdlJfem9JS3dYcEZ6cXBxNnN0UkZvZ3QxQ0xVLVB2V0E1eWRmUkxJUm1lMUcxbXBnMzJFaWJVQkM0WlFUeW04R0pCSmlDbE5VOWRPYmVISWpqSGtRdi1XMlRMUnZoOG5idEdVVUhxT2FpYmJyMmprR05tc3JsaHc?oc=5",
    "summary": "TLX101-CDx Given Complete Response Letter for Glioma Imaging  Oncology Nursing News",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-y6syseoz6",
    "company": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxObE5VdV8wSVA2X2owbDVmal8tUEptWW1FNmpEQjRWU3BMb0dSOXgyaUJuRmRsWFd0TU13bWJnZ2FTLWRDdUphdmxJUUVRYldOb1l6aUxXN0lKSWtOWXhiLWVFdmVwbUJYTVgzdTl2VkgtdDFXY3g3QWhyU1JRdWRFZlBkV0Y4NElDeWN6RVEwMkRPSWM?oc=5",
    "summary": "PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA  Yahoo Finance",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-7jj7mi4hg",
    "company": "FDA hits Unicycive with manufacturing",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect - Fierce Pharma",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcHNsMWNuaTNURmo2SVJ0MkZwczNsNkREY2g1bG1XRnRZREUyTlFreVZNYXdlNkJYMjZBV3FwQ2twZmQtOHRPUzNvR2tRNVpFbWxVT01paU9VcGFSQjhMblpFZzg3U25iRlNIZGxaQXFVUTBYb1R6dTVrbzYxamZtUERSazFfS2xIY0g5dGR5ekI0RndTM0lyN3pPc2pnTGhPaklOUVJpZ0FfbW04eUNwVW1kMDAxSmh6QnhRYXlkS18?oc=5",
    "summary": "FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect  Fierce Pharma",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-nvossroq8",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-10T07:00:00.000Z",
    "title": "Just how radical is the FDA's complete response letter move? - pharmaphorum",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOQlpqYUp3SmJZY2JTam1VUGhNdHh3YWFjdXN3OWYxYkhDbnNLWVJqUWoySHpqWnlwdnRlNXJYWGwwclBwOW9NdllJX1c0RWRjaHpleDVpbHlMVkFkM0NxUzA4N0wwU0FUQXNBMWpIWnpWMVV1OUl2U1liY3luODUzQzRUcG9NNmxs?oc=5",
    "summary": "Just how radical is the FDA's complete response letter move?  pharmaphorum",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-1aoax6wmd",
    "company": "Unapproved Drugs",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T02:37:30.000Z",
    "title": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency - insights.citeline.com",
    "link": "https://news.google.com/rss/articles/CBMipAJBVV95cUxOcEZXX3lHVGtLX3BPSXR1UHBOdldTRzdJU0lhRlVHRDRETko2X3ZVU3pweklvQjk4cW1GWDJpeE0xbjdScVBGa2lUNWQtbGZJWHlYMkZXQmRwQVhRRnlDZkpfVklENVN3ZUNXMUExRGdNWjNwV0lJemQwZ2FZMHR3TFRadUlwYnF1TjJPQlhKdEw1cHZDSV9MS0JpckVhemtSRlJBNlJFV25IZ1dEQk9mSHUweVExYVExczlVY01ER3pqak1weWpXX2VrbjRjUVFNTEZHdXVkUnc5SldtZ2ZrUmxjVVhCX3ZFaXNNYnY0Wmhwd0VEQnhnb3hSMVRONVRzWGdwVHJuQjNTX1c3VV9VY2wtX0NhOEJXSGVYcExfd2JOVmpV?oc=5",
    "summary": "89 Complete Response Letters For Unapproved Drugs, One Huge Leap For US FDA Transparency  insights.citeline.com",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-go2j5lr7p",
    "company": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOejFVV01XY3BDalhBT3lkQU9OSE1icjl3dkJWRjI3aDNxeHNjTXhBdXl5c19DMTh1S3FpM1ZtTFRBX2FDZFltbGRkVEt5VlVDLWF1SEJCdDZKNFZfeWozX00wQTZ2UTBFRXZWeDdoRzcySldnRHZrZ21EcVpQd0dSaXVDVEdxOUlmUm1mNWZpMXJORUNYVnBrN0dwUkxJRzlzVHlCNm1jM2xRRWQ4SWpOY3BabDVJT2N3S3NFal8xOU94U3ZG?oc=5",
    "summary": "Outlook Therapeutics Receives Complete Response Letter from FDA for ONS-5010 BLA Resubmission  Quiver Quantitative",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-0tb5kqdzu",
    "company": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy - FirstWord Pharma",
    "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBalJyWmlNZjQzUWxrRFpsVm9XTGhwMlFBWVd6QUw3S280U1JWX0NQbWZVTEEyVVhvVHF6VHBlenJoOTFHTlB2UnhNOHZqSW9Cck5v?oc=5",
    "summary": "Ultragenyx gets FDA complete response letter for Sanfilippo gene therapy  FirstWord Pharma",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-ehg054h0x",
    "company": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-30T07:00:00.000Z",
    "title": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment - Neurology live",
    "link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSEJkaW1DYnZ3THRNTWdpc2hNMFh6dXNPUHdFUXoyRjlwWnRQVzZybXNGMmtDOHdsVnA1M0NIU0UxVUlGQTYxLWVIM0FmcGlFMWY2VFlXMTZINVNfRmppWjMxRlY1VWVXUE1GVjJubTRZTEdrOE1GZXNqV1QwbEZLcFBNYTFYTVNRTno5UUhibG04QW5LUUNuTFZTdFcxTERoYWo3Y2tLQ3lvV1ZkS0EzcUY4Ulp5LXd5V0E?oc=5",
    "summary": "FDA Hands Capricor Complete Response Letter for Deramiocel as DMD Cardiomyopathy Treatment  Neurology live",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-s8u3u7zn2",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T13:56:19.000Z",
    "title": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA - Contract Pharma",
    "link": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPN1Zpanp6WWlzNWUzRnl4NXRpOFdWWVRRRE1laGZZdGRJbDVzWFZ6Q0N5T1F0MkRQbEgwc1FmNzB3X1Jqc1lTa3VEMm1vMExiRUFtNENZRUNabWR4anQzMWJGcXZHcXV5NUI5QjZBQmxINnQxMnJlN0JOTEh2aXJpUGVqczFPTU01N1QtUFdBNjhzNHN1VVlFOTZ0WjdtcUlTSWxBWA?oc=5",
    "summary": "FDA Issues Complete Response Letter for PTC’s Vatiquinone NDA  Contract Pharma",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-105l2e8x4",
    "company": "Ultragenyx receives complete response letter for UX111 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Ultragenyx receives complete response letter for UX111 BLA - Pharmaceutical Technology",
    "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOVUszb2g2NjVsalpmZlZPTmpybFNBVHBiWFRvNHY3NVJhRm1LaTNiMkdjTklkMndSWmFUMDFFTkt6ZXFNYU1ZYkM5QzZEa2NCN1g0MzlmLVRaN1VYdVdCbkdOVzlJRlBXYUVjM3U5Yk5WbEFVVl9KV0NZZjkwSkpMQWc4UDVkekJDUmRTNVFqWllYTHM?oc=5",
    "summary": "Ultragenyx receives complete response letter for UX111 BLA  Pharmaceutical Technology",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-b2fvf2ivq",
    "company": "FDA received complete response letter from FDA for Columvi in DLBCL",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-27T22:51:27.000Z",
    "title": "FDA received complete response letter from FDA for Columvi in DLBCL - PPF Group",
    "link": "https://news.google.com/rss/articles/CBMioAJBVV95cUxNWXhMcURoaGVLOVlfV2lBN01uc2VuRTU1TVlxcE1kdkFQekNETjRFRW83M3huT3lIRFMxY0xCOWtCVzFKd0JSczc2TV94bXN5TlVWWjVKQm5nMkUzRWhwdDZPYWdrZ3l0d2JUYWFSQXNCeE44aTNQTGVBRG5vVWhvRExPUnhUMzBibUFJTFIyWGFjOGpGblR0Y0hHUy1oTDQ3RjdTY29jS0VzX1hzWF9QYktyaHlPR2RmMGVCX0xGSVRMNC1iUjlacnRlZndmeG5qVVl6ZFdMRkRBUGhpd3BFbjhhWVZWQlRoNFloYWYyQ25jTUZRZXhkSGFzY0ljODVxbjBCZHhKN2pCSmloR3oxSzdxRXJCbGNlaXVwOGVlNnU?oc=5",
    "summary": "FDA received complete response letter from FDA for Columvi in DLBCL  PPF Group",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-dhhp560ct",
    "company": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T07:00:00.000Z",
    "title": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen - Curetoday",
    "link": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPNi0yMDRsekFtZmMwZFB3cjdOekF6WGxiUnJPWnBPMU5RQVBkaVZCVlh3SlJKSGgtaXdTcjZraTNJSVpzMXBNUDR5aHJZUlF4YzNQUk85VVpsRFRKNzZmOTFKNWcwc21oeGQ1dkY5UDBpZWdpaUdLbFhBdkdIVkF0VUdfZXd5ek5PQklmM2dQU1Rtb2hQQUE?oc=5",
    "summary": "FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen  Curetoday",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-36n9sy5b1",
    "company": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-02T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQMWtoZlFGel9acHZOWlQyMm9sS3FhYUpjd240RVZRTGY3WmZkNENTZndFSGVfSUx2UWRBcHJybzlyZWZQTHMxZmNRNWZaWTVJeXBRYmhnM3gxTVA2bFBLY1RRLWNtRFF6dTJjdHpsajh4UXE0aU9PeGtjV1Fsclc1QUNTRWNZZG4zRjVzQWFxd1BhQjhWN1pwODNicXY1VERZYWZTMFBheTBuY2FDMVlXZjFwU0dTSnI4RGd5dllFbGZEYjczemlyRXdKMHBRTVotQXVB?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of OLC, Treatment for CKD-Related Hyperphosphatemia  Pharmacy Times",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-5kr3ge7jq",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T17:28:42.000Z",
    "title": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZmF0a0F4VGs4MjA3QlpBRGJxcjlzODF4dlN6XzVYbnN4OElBWFdxNUpNOTBvZG9ya2JWWWVDV1VfdjNyUkpLSW41QmYxSGdGSWZESzA3emJGQUROcnpfU0JKa3RvT1JHN0JLaEc0SlJBSHlSU1ZwcHZZcFpfVHd6Q3NfYmxzSkh1?oc=5",
    "summary": "Telix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response Letter  Yahoo Finance",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-6dm3q2r75",
    "company": "FDA Issues Complete Response Letter to Outlook",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T21:45:00.000Z",
    "title": "FDA Issues Complete Response Letter to Outlook Therapeutics - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPVzdiX0sxNnREVi0tSHBPaDhrZngtQkRYRnE4c1VKVFRzcHVtSVZRN3l2TW53a19QeUlEdlROaHd3cWxITVdFODM2bWV4LW5mclVYLWFHNlRIYnpTSHpMUkJ6ZjFDMG5DSVd6ZDk1V2R3LUg1ZzE1eFFfUHNpVFRUY01POTVveHRtTl9lWlczdUZkNHVRd0o0cFptT3JJSnpBMWdCSllEWEI5Sk4wX2lYZA?oc=5",
    "summary": "FDA Issues Complete Response Letter to Outlook Therapeutics  TipRanks",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001626-0yc5m2ujx",
    "company": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbF8zbDVUalRyb19zVnJOMmMxWVZWc1U3UEgtRWpWTHhUOTVzemwyQ3A3Ykw0dHlqTl92VWVRWkphZ3ZaUVEwVXd6RHIxSFZKbUw1ZDNRN0d6b2k2cl9xbmZ6UDVUTDAwcnJ2U0w1XzI4blhzMVlCQjRjX2RlVVE4V0J3bXUzRHhFOExDR1N2V09pWlZ0SU0tRGx0ckJWVDA1STh4QXJIQUdDazFMRFYzTHhObTNLQTQ?oc=5",
    "summary": "FDA Publishes Hundreds of Complete Response Letters From First Half of the Decade  Pharmacy Times",
    "created": "2025-09-07T18:00:01.626Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-dd0bvmkix",
    "company": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-22T07:00:00.000Z",
    "title": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma - CancerNetwork",
    "link": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPeUpKUXVENG1XWnEtZHRPR0ttTkdJOUNidUMwMUJvY3pTY3ctS1VNeUd6Wi1TaS1KVks5REdYTERpcUxmTndpVnk5VGtfd2pqUGZvSUFvT2JJTGxOWHpKczh2LUl5ai1NSG9IV1VsLVg0aHlwRThsOXpVZUFiNlBtVVdRUjJ0Skk0eTRkU0g4d3FGQVJRSnFSLUV4OTVxRDVHOHc?oc=5",
    "summary": "FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma  CancerNetwork",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-9fr3l1sc0",
    "company": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:44:00.000Z",
    "title": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNcWk5bGNVVFJRbTlzZnJ0VFp0SFVHcVUyZkZxdS1TSS1aTjBkRlAteTNXbTJYN3dwcDNxYjlrMzFVc2dyX0dLRzdMNmhoVm9hajY0U0xrM3dWaDJfX2UxdkNQVVIxTENQclM1VzJPN0NVdnFXYzZaLUEtbmlNTmxXV05rdEMtVjJxMFhIRmJrZjhtWUtrX2J0cFAwdl9YcFl6cHZqdTFPRGEtb1A1ZXZ3eXJQa1REazdPYWkxZXp6bFE5RkktMXFScjdyWVMtZFM3V2QwVjlsZ1p5WlM1Q2lkM1gyc0dGc3FUTmR0Vk1wQ2dzeXBVaG9TTw?oc=5",
    "summary": "Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application  Quiver Quantitative",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-rcdz3xv77",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZXlhSFNScVd3dFNhSDBQemMyMVpNUExDeXRYNDlYeFNhZ1F5RGlFcmhPbURGX05tZUhkNFpNdVVrYzRQWnpFS0pyZFFabnNZUXRjNzdRazBZdmV4RS1ZLVFUNFVlbjI1ZVZTQ1RZTzJ3NU9hbzZJZ1dDZ1lremdyUENyU2tlRkZwSVNsTHJweWlXLWtXRVZjRVNSYnNMVW1xTUFMZXlHZllZVHFWR3c4MkptbFpjTGM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy  Targeted Oncology",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-amvjwlcus",
    "company": "FDA issues complete response letter for 89Zr",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC - Urology Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTENaRm5KN0ZXT2V2dUpYWWRiTU5RSDA1R18xcU5IcWplcms4b0VxYU8zTllCQUJJU2RJZDNCWGxGS0VUZXhPMGEwTmV0M2gxbXRBMHZFTHlJVC1iZzhTWXlkYnVySWJtZUI1aVN5eFp1R0JGOVhFRlkxcTFIaTU1LUJfaUY2VUxPWXJkd3RqYWVXdk10U3Uya2lvYnUwNWRvTVh6Wm03QQ?oc=5",
    "summary": "FDA issues complete response letter for 89Zr-DFO-girentuximab in ccRCC  Urology Times",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-j6pz4rypg",
    "company": "MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T00:09:00.000Z",
    "title": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPbTRkZFdNRi1Sb0tNQUhQYjFuVnZZVTdJWDJYb2hpOTNLcFRBb0liQmdna1N4amdGak03bHpHVzJ1cUhXMDNyLWJKYmR0QlJGdlk5QmYzYTBpVEVJRFNSSnQzUk1oSWFvNngwZTl1SDFMZTE4VzRZcFp5X2hTRkJ1V0U0aGs4WGtRa0VocHJ3M0l4Zm5acjZNMThaQ0k5QUxrekFoUFVMSWZZTUZrUnJqakZiQTJTUXZ6dWdJOG9fTENFeE5SdGxpUmFWWUJSRlUyZlFFQWZla3l4OHNZU18xal9XWVBwR0o5VUdVbDZQWGdwcWg2dnB3?oc=5",
    "summary": "MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  GlobeNewswire",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-zdnhq5k93",
    "company": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T07:00:00.000Z",
    "title": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times",
    "link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPbHdlN1pFRHhxazgxN1dwTWVOY3B6Uk9tM1hqQ19KNDNOSlNkZE5RUk9qMVZtSDA2WWpfeWFlaDJCOHdlMWgta09FMnU0RkwwQ05fODRpbFpOUDgtNE0zcnJOMUN3b1AtNUk5TzRzdVNnMEdJb2ZjU09KNzRjcURfdU1ZbXE5aHRXMk9fUjNTSzFJT3ZrQVRIdzlIc0dvWXE1dWswUjAxTm5ISHBxSGctU1IxSW81a0FiLVowOGRFLVlUbHlORGdmVlhJRm4?oc=5",
    "summary": "FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010  Ophthalmology Times",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-4ba9l8lp8",
    "company": "FDA Releases Complete Response Letter on Declining MDMA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T18:56:15.000Z",
    "title": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5",
    "summary": "FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD  Psychiatric Times",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001625-2qm0hgl6d",
    "company": "BREAKING",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-05T13:49:44.000Z",
    "title": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL) - Psychedelic Alpha",
    "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPLTd0czdNWWo3UkdpTTNsT2FLUmZpVTlWZFBjUU9oRkRwMjFQdGcyZ2pPUmRuQkNkM0M1ZjBocTBFVWtvaTR3ZUVlYU1odjBtbF93dXJEbGI1dnVWM0k3TUJkdHlPYktNRlRSLXpuZXBnY0czZjdtcnZtYXBEWXJkQnZHTjRQYjhqZjZzS2M2RnFlNTF3c3Jzc1VneklDVTVsakhEcS16ZUU5RWhBbUE?oc=5",
    "summary": "BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)  Psychedelic Alpha",
    "created": "2025-09-07T18:00:01.625Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757268001623-1m4gbgwge",
    "company": "FDA Announces Real",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T13:23:32.000Z",
    "title": "FDA Announces Real-Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-announces-real-time-release-complete-response-letters-posts-previously-unpublished-batch-89",
    "summary": "The U.S. Food and Drug Administration today announced that it will release future complete response letters (CRLs) promptly after they are issued to sponsors.",
    "created": "2025-09-07T18:00:01.623Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-vbsu4iq4r",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-30T07:00:00.000Z",
    "title": "FDA issues complete response letter for Unicycive’s kidney drug - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNek9uUkVPNnlxOWU1Ykdia3RQaDFUTjVXc1FUeHYwMHBGNENSUVlhR3RZUEFoLWhRZlRzUHVwMVowOV9MV1V2Z3UzWHVqaUhDdkx3bXBWTjhDQkRPb0hibllsVnV4MDJVeC1aWkp0eW9rNVQwcVd5UEtUR1ZPSlh2aW5wLW5JR1hOaER5NnMxZ3JtMllGcmZZaHBhTUhLZ0hET1gycEw2WWhfbXVFVkxURXJqVEx3VXBRS2cw?oc=5",
    "summary": "FDA issues complete response letter for Unicycive’s kidney drug  Investing.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-k8k4n18lu",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-20T18:08:52.000Z",
    "title": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdEhEZjBoaVlxbHNHc0drWWxWdzd6cVBIdkhNd2FYeXpyZ0NISnI5Y2VVT3FqSGlVOUdIZ3Rqc0hxeUhja1UwSk9QeEFiZjJkbVB3ZlluaVFyMEkzendEZC10UWZNLWpGTzFkYXpKSmxDMnE0cUdtV05XSzJCRXZvWFEzVUxKUVJIemFJVnNNUHhOX0NINmxiRnFGX1Y2ckF5dmVsX1phVmphbkFtbmU2MW5LTURFbkdVMzh5UmhXYTZLZHR6VG04UUZkSlhwUUR3REZuU29EMGR2RnhMMlRNX2tlT2FBNDVvS292cnBNUlk2ZWIy?oc=5",
    "summary": "FDA Issues Complete Response Letter to PTC Therapeutics Over Insufficient Efficacy Data for Vatiquinone in Treating Friedreich’s Ataxia  geneonline.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-qr1p9gn55",
    "company": "Replimune receives complete response letter from FDA for RP1 BLA",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-15T13:11:52.000Z",
    "title": "Replimune receives complete response letter from FDA for RP1 BLA - MSN",
    "link": "https://news.google.com/rss/articles/CBMiygJBVV95cUxNNUIxb2dzdnM4OC1ERlo2MFpMOFZzZl9IaUNJcVhtSFc5cTd0Nkl4Qmd0T1RXanh0alZDQS12MWlwRDZGdWd1WEo1VHRSUFlXZTF0VElxOUdaVDdUQmE2WUJWZzhoSVFORm1BTmdlZFN0S3VzYy1NZWl5dnZ4RWxpSzF2WWQzT1IwOWN6OTVqUDhJck01VGljOVhvM1VhVGI1WnlOSExhNWV1Nnp5SG1xam9DZjZmZWVDdEFUT3owNnltSUdfM0pnREhxVDhCY01GaFlaLTVOdkhsNlhENlRfUzBEa3BZQXJnelRPWl9MMWVyRlVER093blRHV1JObnJBclRSOWRVem83elV4WE1TVElwb2l3REY3WWxINGtYVm03dS1DWE8tUlRBaHlnaXBVUDdwWVEtV2hUS1I0Z3VqQmhHeTBwVjd1UFE?oc=5",
    "summary": "Replimune receives complete response letter from FDA for RP1 BLA  MSN",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-cnxp07awr",
    "company": "Unicycive stock falls as FDA plans complete response letter for OLC",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-01T07:00:00.000Z",
    "title": "Unicycive stock falls as FDA plans complete response letter for OLC - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNbWJhY2x1N1FEYVBlMktadHBUWE1mSUpMdVRQa21zWVZ6dG5oZ0t1c1ZhYktWZHdiOTEwTzdGQUNPVFhqT3V4UUhrS1huU0M2czZNOFBoNUlWb0x5ZFBzVFJVUkpOM3lZUDRwMHNydmJSZk1kRzBiWFVBcHZ4OGdvaDloWVJ1bXZic2RjY1Zvclh1MUhZc2p2NjVMVDNET2hPajBoU3lXX3FBTk95MVJCQnQ4dENTaU9JMUFGWjJxbUEwc2xWQWc?oc=5",
    "summary": "Unicycive stock falls as FDA plans complete response letter for OLC  Investing.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-ctloseh5v",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdV90QmVuOUpBcXoyc01JNWFHYXVRdFktRDBHNndBM09EbmlFOUtrdy1qR1BQSHp2MnN3MUpiNHozZk4yNWphRzFlcjJPSDJXMkd1X1p3QzFsRHp2SzlJMkltbm5zMERJRjcwVlpHSDh4VTRSYkRNTEU5dm0yMUwyWjV1WGNsNFRrcUtUenhiU0Y0THpLMS1PbEphcC1GSnlzLW1sUmpUcGxFTV9qY1ZkdzAyS1QxM2dSRFkyVl9SMFNtWHM?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx’s MPS IIIA therapy  Investing.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-r1enqwk9t",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-21T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro - geneonline.com",
    "link": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHMyWmRFQ0VxOUE2VW9zdkg3MzQ1S0NnWldQNTcxeV9UM3RERjNKNFZSdzFFZnF2OHRHTThPWDN5cm40Nk1STTNoTkZWUTNwc1BNbkRDTnRaT0F0VzJWUVVTbjMtWEtKanVjRnkwNHZ2ZVM2S1BpUFZhS3FjNnAyVElJRXozdkxGanp4ZHdOdmxQS0FjbEVSaFVvVnk3eUJiYzlURGZEbFh4WW5p?oc=5",
    "summary": "FDA Issues Complete Response Letter for Johnson & Johnson’s sBLA on Darzalex Faspro  geneonline.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-uqo6zq9p1",
    "company": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLTlmaDFOclA3OUhtMkdzQjBtQXk3S1JKbl93VzJBM3R2bGRDRUpWQWQxQnZhY05qS0pOTXhNcnJpZE5jTVJnbmlvR1pGa1EweWc2aFkxTldEUEQ2RDZOaTZsS184ZUYxVHN0YmNEOXZlUUt1N3hqNl9VVjJNQ3BKZ19HQkxYbFBRNWdMYnZ1aWJVdlJxb2RweTBfendMM2NQU2I4NVd0MUo1M21Kc3FqS1oyVWwxWE5pZVVzVHVuZUk2dHJiSmhVcGRicDMyMlNVRVE5b1YyRmRIT3BXRzBCOEZDRzA4TWtFNGc?oc=5",
    "summary": "FDA Issues Complete Response Letter to Manufacturer of Reproxalap, Treatment for Dry Eye Disease, Allergic Conjunctivitis  Pharmacy Times",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-etpt3e2gs",
    "company": "PTC Therapeutics Receives FDA Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-19T07:00:00.000Z",
    "title": "PTC Therapeutics Receives FDA Complete Response Letter - TipRanks",
    "link": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNN0lZVHJyMzNVT2duUjBScTZ3SEQzeDZ6UXc4NjNnNmt6bGJDZENoOUxJc09HeEZXcGR5UW11Z1pxdVUteDR4dWFjV1ZxYXE4UzhSZU1JTUdXamtmbFBkTU1iX0xINHpPalV5clNleDZGVXlib0l6aDJRbkRFT1l6aFV0NzBycXlkemdnZmpXbnlMdFViT2MzbG40Z1dBRkRfRmVZRlJ3RkxGdw?oc=5",
    "summary": "PTC Therapeutics Receives FDA Complete Response Letter  TipRanks",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-0dtdbk9on",
    "company": "Astellas receives Complete Response Letter from FDA for Izervay sNDA",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-04T15:41:33.000Z",
    "title": "Astellas receives Complete Response Letter from FDA for Izervay sNDA - MSN",
    "link": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQNDV4NGotbFBTUmlpWXlhWUFNSTRsMENiSmlTcENtODNFRllNRlRCdF9IcmhMWTdfNndEcXlHMi12cXNkcnN3MFdQSDhDb25hTE1OQ1VTaWw2MFRiQ01xSGJHem9SZ1Jzb3N0SmI2dV9HVDlRV19FdFVSLTE0NEpaRDNsejQ5OW5icmd6WmJFOC1HUVNWbzMzM2FOOFVsdmV4NGFkUTJQWE9ZbFh4QlJTb1B1cjBBQ0RNdmdBUTRDTS1rZDkwQk9yQUN0MjgzU0U2ZDdlcFZqbGc5OFBtVG0wSGhLU2FLUUw3ZXZUZ0JJZzMxcS1yQTFRVFJSZUxnc3QycmR1MGMzNDl3ZWpIbVhBaHc3Uk9JdDBPSzc5MXIxLWFaWlpFckhvRk1EWDlTZE9mWHU1ZU5Tdl9udzY4cWtDajRzZGFfZjdtRV9RZmc5VGZHUQ?oc=5",
    "summary": "Astellas receives Complete Response Letter from FDA for Izervay sNDA  MSN",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-tlkw13bud",
    "company": "Capricor",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-14T07:00:00.000Z",
    "title": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNk02ME02b1NUMHltNGRvNHl4eTRVcTBsZzVVc1NXVEFMX1RCN1lZczg4T2NDNm13VmxWWGpUdFhGNk1rSmlMNS1NcHkxZEREdk5sZ1lwcU9hV2NhQTg4RUo0WGxTLWdZYk1zdm1Jb1FGS0hxRXB1Vi1Kd3ZjVzhxeWQtVlFxeHliZ1FjOTZPVi16eXdFMzJlQmRMRjVpNjhNc0l1aC03T1hPbE43UjBhejRrQXRRNnFITF84TXpEX2haMDJ0?oc=5",
    "summary": "Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter  Seeking Alpha",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-fxm0ig8cs",
    "company": "FDA Issues Complete Response Letter for Much",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-21T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog - Pharmacy Times",
    "link": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWWFneWJYcGkyU3JDOTJtd0s0RERBdGVTenhmRnc3ZEZyWk1jd2V1akNTLU5Ka190WEtVd1NQdHgzTVVxR3NjeVpZWnl0SmtOZ2dkcnhpZHhIMmRNdTlDME1aekJmQkk5SVB4ZE8wclBHd2YzUm5FalY5eDFhamhMY05JUDR4NE8yNkI4enVMZFZTczIxVWhUdlRUMDBqRnFaaFhmdDdXUQ?oc=5",
    "summary": "FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog  Pharmacy Times",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-l4difhu5t",
    "company": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A - Quiver Quantitative",
    "link": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxNM0Z0cGZfaXhxSDVIRU5MazJHU1ZQZGV2UHdLeGR0bFhOMHZuRDZ4V0w0MjZlamlIeDcwbkxOeWFwWEtVdWVtQTRBcnZtVmpjVGk4OUhsRWRfWU9JcEQ3VlVTY1YwRkpMX3RncmVlbXBwbkJhS0NVNFV3QTY0VWJ3WnJ4MW5heGVQd3I0QjdfZzZnX2E4UnRrRHFvVWgxS1p3UzNKVWgxZGRDUlpnUkU5S3dpblk5cDBfeFZaRk9sWTBEcy1OeEI0RVNoOW1SdmpfNmV4eDFGaTAzb0ZObkxuN2RSWS1uQVg0dkp4eFJwN2c1dw?oc=5",
    "summary": "Ultragenyx Pharmaceutical Inc. Receives Complete Response Letter from FDA for UX111 Gene Therapy for Sanfilippo Syndrome Type A  Quiver Quantitative",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-ur2z6twlf",
    "company": "FDA Issues Complete Response Letter for Etripamil for PSVT",
    "type": "crl",
    "severity": 9,
    "date": "2025-03-28T07:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Etripamil for PSVT - Yahoo Finance",
    "link": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPRTF1MV9aZ28xSjc4c2dMQ1ZEaFlqa0tHQUZBMkhnY1R6Y0x6eC1aVnQtVV9rQVpWeFpPOFo4MldTRlgwN3MtMWdJZ1pLVVJsUFBWeFBqejVPQTBkMEdrUDNKYURTeTBaR3RLVlBqdTZmWkJIdWhDMDdiTEIxUDBRNGVfUENPeHJM?oc=5",
    "summary": "FDA Issues Complete Response Letter for Etripamil for PSVT  Yahoo Finance",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-lwqyii5us",
    "company": "Milestone submits response to FDA Complete Response Letter over Cardamyst",
    "type": "crl",
    "severity": 9,
    "date": "2025-06-16T07:00:00.000Z",
    "title": "Milestone submits response to FDA Complete Response Letter over Cardamyst - Seeking Alpha",
    "link": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONHV4ZmJtTkl4X21OZVFyU0t4VkpBVTFmMWZVS3JSd3BBa1Y3Zzk1OHo3NFNwNldHUjBSU1BoRlhnZWpRWFQ0Y3lDRlYyWk1QVUhlaHZaX0tXbFNyMnFxeTZKMmw2LTBfalF2ZFRQRmdMd19vMklBRkZiQkFjTWZBTGZCbWcta21MNGIzVUpOOXFPT3FzenNrMUJabTNfS3RmWEZ3MzVR?oc=5",
    "summary": "Milestone submits response to FDA Complete Response Letter over Cardamyst  Seeking Alpha",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-x77x7ukts",
    "company": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease",
    "type": "crl",
    "severity": 9,
    "date": "2025-04-03T07:00:00.000Z",
    "title": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease - AJMC",
    "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPTVJjUHd1RjA1bWxfSGppdGtNZ1RwcVlOTEY0VGR2S3J6NFd0bFdHUy04VlNKMk9aMU5NOTMzc3dta2ZBZENwT0gyNzdmdUJnenR5em1ZTUNSVVMwTUNyMW9WX1JMRlh2TUxDdVc5eVJaRmFYMEg5b2VuSHpfYnM1WHUtMzJoQQ?oc=5",
    "summary": "Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease  AJMC",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-kx38vuj8q",
    "company": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWmFTT2hrVEZfZ0NuZ2x0aWFmSmNDMEQ4Nk1XYUFpc3lJTHAtOEFYS2R5SkhOc19vX05MUkpGVmNucEFrdTZqVERncEg2ejlTWjU0cnVRUllNWGt2N0lQM1NaV2puaERWZVNFMXYwbDA3M2tFSDc3b3MwakhLYlA4TkZnbThXUm1XQTFjVFZkVjYzMnZXbW1SanZWRGlmNlF3SnpINndMdlhqb3VPXy1LaGNudkFoWGdVUjF3cWhfeF9FY21vUktJNUtlOWJucklqb1gzWWcxU2pxbEU?oc=5",
    "summary": "Ultragenyx stock falls after FDA issues complete response letter for gene therapy  Investing.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-vechl0xw2",
    "company": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma",
    "type": "crl",
    "severity": 9,
    "date": "2025-09-02T12:56:17.000Z",
    "title": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma - MarketScreener",
    "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcjNUVWlfM2wxTnQ1RTlLU0wyYVAtZWNiQnpITDN0Z1dIeTNUS3ZYTXY4SnppYmpReWdpWUI5TlgzUWtMQVVMd0tzVGFYTUE3ZThyMjZPWEM4ZWhDMGJHajZrZDJ1LTZ0VUJNUlZkRDhCWmFOakVjZVJzY1BRTG04U3B5WEl4MlZYSzFiWWdLUmtiVEZabXZ6cHZ3ZmNVTjFTanNQTktvUExmbnJaa3RDUUFCN3A2Q3pxQlJYRE1HVVprdFFVZlVPYldCSm1KaUlnQ1FIQU55aw?oc=5",
    "summary": "Replimune Schedules Meeting With FDA for RP1 Complete Response Letter to Treat Melanoma  MarketScreener",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-2d6r9w1z0",
    "company": "Unknown",
    "type": "crl",
    "severity": 9,
    "date": "2024-12-17T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC - OncLive",
    "link": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNcDhYRTAzSEdTSzI5OGJ5UGFnWGxWMERJME9Vam1vUTdmYkZtNnJua082QVJaQnB1UEEzbWVDVVpaMGJPaWZrZ1o4YnE0aFVWUzBaai1rVGVwLUFQbWFkRkRpaUd6RTA0aG9GUXRnd1NJQlVYSFRrdEFlSVRXdjdEUUpDSzdpZHplT2ljdGlkOXBjNDdndi1tbk1XOWNscWhSUXpwXy1rZkpuRXFMUmQw?oc=5",
    "summary": "FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC  OncLive",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-be41130vc",
    "company": "Ultragenyx Receives Complete Response Letter from FDA for",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "Ultragenyx Receives Complete Response Letter from FDA for - GlobeNewswire",
    "link": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxQenU5QmFnQWU2bXNmUGZrM2pZVkhXLUw5RHBQc2huSFc0UlFQdkhMVVJyM2FwdmNvTHRYR2RWbVRtWGNxeVdoOFZvX1gwWmdDX2ZBVzVKVTdOenNOMHh0X0tEa3Vxa3lDQmFGUGlPTThFSUxINFNBeGIyQmMyeW5HdFF6WGNmNHJIU3ZGc05GX1hiMEFnYXA1aERGdEhDNTdfc0gxVV9laS1YOHZ0Z3Y3NV9MdFNkaC1RQzNpMUtaYXZKT3Z3bUV1YVBBXy1HZDk5cGhlYW1udkZVQmVnTGtJWGp4bFlnMkFSQnlGSWg3YjB4eXB3b2M1R05YaE5FdUU1V1VxczBGX0V2aV82STZiMDFOQ0loSVZPNF9XQXM4dmhHWlpzZDVKUw?oc=5",
    "summary": "Ultragenyx Receives Complete Response Letter from FDA for  GlobeNewswire",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-isvhw2lf8",
    "company": "FDA Issues Complete Response Letter for Tab",
    "type": "crl",
    "severity": 9,
    "date": "2025-01-16T08:00:00.000Z",
    "title": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD - Targeted Oncology",
    "link": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPRWpwOHNXTXU1SnYwOElkLXphQ010LWtqUWFva2Z0bjVLS1p0d0Z1VGpLRnlaUTVFRDZpQWlBME9xZURmaWlGNWdfMTZiMl9KN3FJbTRlbEQzODhXWHMyRnd5cGQ4d2E1N3p4WVQ0a05FQzRES0pZUGtjanpyZDhLMVNSUTZ6V2lQQTZxNkphOEtGMkdlb2Q4?oc=5",
    "summary": "FDA Issues Complete Response Letter for Tab-cel in EBV+ PTLD  Targeted Oncology",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-4baadbd1l",
    "company": "FDA issues complete response letter for Ultragenyx gene therapy application",
    "type": "crl",
    "severity": 9,
    "date": "2025-07-11T07:00:00.000Z",
    "title": "FDA issues complete response letter for Ultragenyx gene therapy application - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQdS1qUDhaaDlELTdWRElCUG1mT0RlNDVLc1ZmSndvNEVMSlk2ZjVoSjk0cENpTV9lRU1SQ1V5SzMwckxLck51N2VkQ3ZkSUFEeTNESjZjLUREOTVaV3VHa3VDOWNfS0VxaXpWTk1pRUdQaWZkdi1BdlRORGRaaWdXeExBWmk5am4xUXBpWkFDNWg5bmZmUTUxeEhMSE1zZUVIS29YWmV2VHB3VnRvOW51WVctODF2dW5iMVBxdzFPcnpyZGUtNk1aSktEYw?oc=5",
    "summary": "FDA issues complete response letter for Ultragenyx gene therapy application  Investing.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  },
  {
    "id": "alert-high-1757266612925-xrk9y9ilu",
    "company": "Telix stock plunges after FDA issues Complete Response Letter",
    "type": "crl",
    "severity": 9,
    "date": "2025-08-28T21:22:30.000Z",
    "title": "Telix stock plunges after FDA issues Complete Response Letter - Investing.com",
    "link": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQzhRQXF1ZTZPeVg1NDFjUndCMGNWWEYyYlFkb2tuMnR3cnNvWGlrdjQzZkUxQklENG16UTJjU2VyVXlNTzRMTXpzOHJLVE1BaHFDcUV4YzdOUWFUUHR5b1JjTVZ1Q0htZ0tqSFN1SXE4RjI5N0FkcTRucWlGcU1CSGE1TTZTRFhYWjJmQ2R2MWpqRkRDLUFCenRiS2F1emVEQmxPTzBoaEo4MkFvd3RGSXZuS1A2d0FGWC16bWZxU1o?oc=5",
    "summary": "Telix stock plunges after FDA issues Complete Response Letter  Investing.com",
    "created": "2025-09-07T17:36:52.925Z",
    "high_severity": true
  }
]